Daratumumab interference with blood‐compatibility testing after autologous stem cell transplantation.

Daratumumab interference with blood-compatibility testing after autologous stem cell transplantation The patient completed treatment with Daratumumab in October 2021 having received no blood transfusions throughout this time. In March 2022, 6 months after last dose of Daratumumab, two separate pre-transfusion samples were tested in the patient's referring hospital and showed no interference with serological tests, giving a negative red cell antibody screen. [Extracted from the article]